Despite major strides in the treatment of cancer, the development of drug resistance remains 2 a major hurdle. To address this issue, researchers have proposed sequential drug therapies with 3 which the resistance developed by a previous drug can be relieved by the next one, a concept 4 called collateral sensitivity. The optimal times of these switches, however, remains unknown.
(a) Drug resistance (b) Tumor heterogeneity and collateral sensitivity Figure 1 : (a) General dynamical pattern of disease burden. It increases initially and then decreases as of the therapy starting point (t 0 ), and eventually rebounds after the maximum period with positive therapy effect (T max ). Relapse is found, at the earliest, when disease burden reaches detection threshold at t DT . (b) Change in composition of tumor cell population when a pair of collaterally sensitive drugs are given one after another.
The underlying dynamics of resistance development has been studied by looking cell popula-tions mixed by sensitive and resistant types against therapy/therapies, whether it is genotypic or
Figure 2: Diagram of dynamics between sensitive cells population, C S , and resistant cells population, C R , (on the left panel) and the differential system of {C S , C R } (on the right panel) with s−proliferation rate of sensitive cells, r−proliferation rate of resistant cells, g−transition rate from C S to C R Figure 2 shows the diagrams of such population dynamics, and the system of ordinary differen-91 tial equations that {C S , C R } obey. The solution of the system (1) is
where {C S (0), C R (0)} = {C 0 S , C 0 R }. By (2), total population is
95 96 C P (t) is a positive function comprised of a linear combination of exponential growth (e r t ) and 97 exponential decay (e −(g−s) t ) with positive coefficients. Despite the limitations of simple expo-98 nential growth models [23] , we feel it is a reasonable place to start, since the relapse of tumor size 99 starts when it is much smaller than its carrying capacity which results in almost exponential growth. In addition to T max , another time point with significant meaning is T min , explained below. Since 135 the decreasing rate is almost zero around T max with no switch (see the black curve of Figure 5 ), we 136 seek to find a way to expedite the decreasing rate by switching drug before T max . 
144
This comparison reveals that the two derivatives are equal at a specific point (this is T min , see the 145 yellow curve on Figure 6 ), the derivative of drug-switch is lower (higher in absolute value; higher 146 decreasing rate) if t 1 > T min (see the blue and green curves on Figure 6 ), and the derivative of 147 no-switch is lower if t 1 < T min (see the red curve on Figure 6 ).
149
T min depends on the parameters for the first drug {s 1 , r 1 , g 1 } and for the second drug {s 2 , r 2 }, 150 and initial population ratio between resistant cells and sensitive cells for the first drug RpS 0 . Here, 151 transition parameter of second drug (g 2 ), and respective values of the two populations are unneces-152 sary in the evaluation of T min , which is found to be 153 T min ({s 1 , r 1 , g 1 }, {s 2 , r 2 },
In DrugA-to-DrugB switch, it is T min (p A , p B , ApB 0 ), and in DrugB-to-DrugA switch, it is 154 T min (p B , p A , 1/ApB 0 ). 155 156 Figure 6 : Comparison of total population curves with one-time drug-switch from DrugA to DrugB at different time points, (i) at < T min (worse than without-switch; red curve), (ii) at T min (same as without-switch; yellow curve), (iii) between T min and T max (better than without-switch; green curve), and (iv) T max (better than without-switch; blue curve). Each color of dot/curve represents cell population level on and after drug-switch of each switching strategy. The dashed curve mixed by yellow and black colors represent the yellow and black curves overlapped. Parameters:
An important issue observed in Figure 6 is that the population curve with only one-time drug-Optimal drug switch scheme will be discussed in detail in Section 4.2. The optimal scheduling 167 for the example of Figure 5 starts with the first drug until T min (blue curve for 0 < t ≤ T min ) 168 followed by rapid exchange of the two drugs afterward (black curve for t > T min ). Switching 169 before T max , that is, before the drug has had its full effect, goes somewhat against clinical intuition, 170 and is therefore an opportunity for unrealized clinical improvement based on a rationally scheduled 171 switch at T min . In order to realize this however, there are conditions about the order of T max and 172 T min which must be satisfied. In particular:
In our analysis and simulations, we will deal with the cases mostly satisfying r A r B < s A s B , as 174 otherwise we cannot expect improvement of clinical strategy using T min , and more importantly as The difference between T min and T max (T gap ), provides intuition on how much shorter the first 179 drug administered than it is used to be.
180
T gap ({s 1 , r 1 , g 1 }, {s 2 , r 2 }) := T max ({s 1 , r 1 , g 1 }, RpS 0 ) − T min ({s 1 , r 1 , g 1 }, {s 2 , r 2 }, RpS 0 )
We studied sensitivity analysis on T gap over a reasonable space of non-dimentionalized drug pa-181 rameters in Appendix B. Expectedly, as the proliferation rates under the second drugs increases 182 (r 2 ↑ and/or s 2 ↑), the optimal switching timing to the second drug is delayed (T min ↑ and T gap ↓).
183
As r 1 increases, both T min and T max decrease. However, T max decrease more than T min does, so in 184 overall T gap decreases. s 1 and T gap do not have a monotonic relationship. T gap is increasing as s 1 is 185 increasing in a range of relatively low values, but it turns into decreasing in relatively high values 186 of s 1 . In this section, we study how the degree of cellular heterogeneity and therapy effect are related, 189 and checked the roles of T min and T max in the relationships. We defined a function of population 190 makeup ApB based on the ratio between the two cell types,
And, as s < 0 and r > 0, those values of ApB are all positive. Ef
The effects of DrugA (specified by p A ) and DrugB (specified by p B ) defined in this way are equiv- and increases as ApB increases above ApB(T B max ) (see Figure 8 ). Figure 8 : Effect of DrugA and DrugB over the axis of ApB. The two drugs have same effect at ApB = ApB * , and have no effect at
The drug effect is getting bigger, as ApB is getting farther from the no-effect level to the direction of getting less cell population resistant to the drug.
The population makeup changes in the opposite direction. As DrugA (or DrugB) therapy 212 continues, ApB continues to increase (or decrease). So, if DrugA (or DrugB) is given too 213 long, it should go through a period of no or almost no effect around ApB = −s A /r A (or around 214 ApB = −r B /s B ), but once the drug is switched after that, there will be a higher therapy effect with when the population makeup reaches ApB * .
Depending on the condition (6) In this sections, we describe a drug-switch strategy to achieve the best effect possible with a pair of 226 collaterally sensitive drugs. It is numerically found, and consists of two stages. through DrugB therapy (∆t ), and finally (iii) taking ratio between the two therapy 237 periods (k = ∆t/∆t ). k depends on drug switch frequency and model parameters,
Such k is consistent with k , which is the ratio similarly evaluated with DrugB as first therapy and DrugA as follow-up therapy, in the optimal case of instantaneous switching,
We studied how sensitive k * (or f * = k * /(1+k * )) is over a reasonable range of non-dimentionalized Figure 10 : Comparison between dynamical trajectories of the optimal (T min switch; blue curves) and a non-optimal (T max switch; red curves) therapeutic strategies. Part of curves over Stage 1 and Stage 2 are drawn in gray and white backgrounds respectively. Parameters/conditions: Figure 10 shows examples of population curves with the optimal strategy (T min switch) and 243 one non-optimal strategy (T max switch) using the same choice of parameters/conditions. The vi-244 sual comparison validates the better effect of the optimal strategy than the other strategy over a 245 range of time (see Figure 10 (a)). Figure 10 (b) shows the typical pattern of ApB in the optimal 246 therapy compared to the other, which is monotonically changing toward ApB * in the first stage and 247 staying still in the second stage.
249
For the sake of practicality of clinical application, instantaneous drug switch in Stage 2 could 250 be approximated by high frequency switching with ∆t 0 along with the corresponding k(∆t) 251 from (9), or k * (10) independent from ∆t. Expectedly, the smaller ∆t is chosen, the closer to the 252 ideal case with ∆t = 0 (see Appendix C for the details).
254
Additionally, we have proved that the effect of instantaneous drug switch, with an arbitrary 255 ratio in duration between two drugs (k), is consistent to the effect of mixed drug with relative 256 dosage ratio which is also k (Theorem A.8 in Appendix). The theorem is used in the derivation 257 of differential system/solution of optimal strategy (Theorem A.11 in Appendix). According to the 258 results, in Stage 2 of optimal regimen, all types of populations, A R , B R and A R + B R , change with 259 a same constant proliferation rate, Our stochastic model depends not only on net proliferation rates (s, r, see Equation (1) (Figure 11 (a) ). The time at which one of these events occurs is determined by an exponential 271 probability distribution, and we represent the algorithm as pseudo-code thus: Step 2) Update from t to t + dt:
276
(random number generation) Increased I stoch result in larger fluctuations (Figure 12 (b) ), these fluctuations then increase the 307 probability of reaching an absorbing state, in this case extinction. The relationship between I stoch 308 and extinction time is shown in Figure 13 . The relationship is significant (p < 0.05 and r 2 = 0.1726 309 with slope= -93.68 days 2 ). The emergence of resistance to our presently best therapies is a sad, and conserved reality in the 312 oncology clinics today. While much effort has been put into novel drug discovery to combat this, 313 there is also a growing interest in determining optimal sequences, or cycles of drugs that induce continued (or collateral) sensitivity. To study this second scenario, we proposed a simple dynami-315 cal systems model of tumor evolution in a heterogeneous tumor composed of two cell phenotypes.
316
While in reality, cell phenotype can be defined in many ways, here we completely describe it by 317 considering only sensitivity (or resistance) to a pair of collaterally sensitive drugs, which is en-318 coded in their differential growth rates in specific conditions. While the resulting mathematical 319 model conveys only simple, but essential, features of cell population dynamics, it does yield ana-320 lytical solutions that more complex models can not.
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Appendix A Derivations of explicit expressions
for any positive integer, n, and for all
Then, we need to prove that F (n) = L for n = 1, 2, 3, ... If n = 1,
Otherwise, if n ≥ 2 and F (m) = L for all 1 ≤ m ≤ n − 1,
for any positive integer, n, and
(by Proposition A.3 and Lemma A.5)
The equality is true for n = 1
If n ≥ 2, and the equality works for all integers 1 ≤ m ≤ n − 1,
(by the inductive assumption and Proposition A.3 and Lemma A.5) 
Proof. For any time point t 0 , let us define V (t) as a vector-valued function of A R (t) and B R (t) describing cell population dynamics under periodic therapy started on t 0 with DrugA assigned on t 0 +m ≤ t < t 0 +(m+f ) and DrugB on t 0 +(m+f ) ≤ t < t 0 +(m+1) for m = 0, 1, 2, 3, .... Then, by Proposition A.1 and the definitions of A and B,
. And, V 0 (t) represents instantaneous drug switch.
For any ∆t > 0 and any positive integer n, there exists = (n, ∆t) such that ∆t n + 1 < ≤ ∆t n or 1 ≤ ∆t n < 1 + 1 n .
Then by the squeeze theorem, lim ∆t→0 (n, ∆t) = 0 for any positive integer n, and lim n→∞ ∆t n (n, ∆t) = 1 for any ∆t > 0. · · · ( * 2)
For such ∆t, n and (n, ∆t), V (t 0 + ∆t) is bounded, since local extrema can occur only at which drugs switch by Proposition A.2. That is,
Similar to (*4), lim ∆t→0 lim n→∞ V (n,∆t) (t 0 + (n + 1) (n, ∆t)) − V (t 0 ) ∆t
By (*4) -(*6),
· · · ( * 7)
Then, by (*3), (*7) and the squeeze theorem,
Therefore,
A.2 Population dynamics with the optimal regimen 514 Lemma A.9.
ApB * and f * from (8), (10) and (13).
where U = 1 −ApB * along with
is an eigen pair of D * .
519
Theorem A.10. In Stage 2 of the optimal strategy, both A R and B R changes with a constant net-520 proliferation rate,
Proof. Without loss of generosity, let us prove it only when ApB(0) < ApB * .
524
If ApB(0) < ApB * , DrugA has a better effect initially. So following the optimal therapy scheduling, DrugA is assigned alone at the beginning as long as T A min = T min (p A , p B , ApB(0)) (Stage 1), and then Stage 2 starts at T A min with initial condition
By Lemma A.9, V (T A min ) is an eigenvector of D * with the corresponding eigenvalue, λ. Then, 529 the solution of (*2) with the initial value (*1) is If ApB(0) < ApB * ,
Similarly if ApB(0) ≥ ApB * , (1 − s 1 )(r 1 − s 1 )(r 1 − s 2 ) r 1 ((r 1 − s 1 )(r 2 − s 1 ) + (r 1 + r 2 − s 1 − s 2 )) 1 + r 1 − s 1
In general, cells mutate in a slower way than they proliferate (ref), so we ran sensitivity analysis 549 on T gap for all a 1 for a ∈ {−s 1 , −s 2 , r 1 , r 2 }. Figure 14 shows T gap over the range of 20 ≤ 550 −s 1 , −s 2 , r 1 , r 2 ≤ 100. So, under the assumption that g 1 min{−s 1 , −s 2 , r 1 , r 2 },
which approximate the contour curves of Figure 14 . (6)) Regarding the regulated intensities among the two drugs, k * , we assumed that g 1 ≈ g 2 := g, 555 similarly assuming that they are both much smaller than {−s 1 , −s 2 , r 1 , r 2 }. Then we normalized 556 all the parameters with the unit of g, like 557
{s 1 , r 1 |s 2 , r 2 } := 1 g {s 1 , r 1 |s 2 , r 2 }. 558 k * can be rewritten in terms of the dimensionless parameters. 559 k * ({s 1 , r 1 }, {s 2 , r 2 }) = (r 1 − s 2 )((r 1 − s 1 )(r 2 − s 1 ) + (r 1 + r 2 − s 1 − s 2 )) (r 2 − s 1 )((r 2 − s 2 )(r 1 − s 2 ) + (r 1 + r 2 − s 1 − s 2 )) (12)
In sensitivity analysis, we use 560 f * := k * 1 + k * ,
which represents intensity fraction of initially better drug out of total therapy. We evaluated f * 561 over the same ranges of {s 1 , s 2 , r 1 , r 2 } like the previous exercise. (see Figure 15 ) Over the ranges, 562 max{g 1 , g 2 } min{−s 1 , −s 2 , r 1 , r 2 }, so k * and f * can be approximated by simpler forms.
k * ≈ r 1 − s 1 r 2 − s 2 and f * ≈ r 1 − s 1 r 1 + r 2 − s 1 − s 2 564 Figure 15 : Contour maps of f * over ranges of 20 ≤ a ≤ 100 for a ∈ {−s 1 , −s 2 , r 1 , r 2 } and r 1 r 2 < s 1 s 2 (Condition (6)) in the optimal strategy 566 In clinical practice, the instantaneous drug-switch which is proposed in this research to apply in the 567 second stage of the optimal control is not implementable. Therefore, we studied similar schedules 568 to the optimal case, and compared the therapy effects between the different schedules of admin-569 istrations. In the "similar" schedules, the first stage with an initial drug remained same to the 570 optimal schedule, but the second part of instantaneous switch (with ∆t = 0) has been modified 571 into fast switch (∆t 0). Figure 16 shows how the effect on population with instantaneous switch 572 (∆t = 0)and fast switches (multiple choices of ∆t 0) are different for a choice of drug parameter 573 values. Expectedly, the smaller ∆t is chosen, the closer to the ideal case of therapy effect. And, 574 a choice of reasonably small ∆t (like 1 day or 3 days) results in the outcome quite close to the 575 optimal scenario.
577
We simulated same exercise with k * (from (10)) instead of k(∆t) modulated by ∆t ( Figure   578 17). Only invisibly small differences has been observed between Figure 16 and Figure 17 , which 579 justifies general usage of k * independent from ∆t. Figure 16 : Graphs of regular drug switch in Stage 2 with different {∆t, k(∆t, p A , p B )}: ∆t = 1 day (blue), ∆t = 4 days (red), ∆t = 7 days (green), and ∆t = 10 days (magenta). Parameters/conditions: p A = {−0.18, 0.008, 0.00075}/day, p B = {−0.9, 0.016, 0.00125}/day and {A 0 R , B 0 R } = {0.1, 0.9} (a) Time histories of total populations, C n P for n ∈ {1, 4, 7, 10} days (b) Differences between the optimal population history C * P , (i.e., when ∆t = 0) and each cases with positive ∆t. (i.e., C n P − C * P ). The inside smaller plots are same types of graphs with the bigger graphs, and show enlargement of interesting ranges. Figure 17 : Graphs of regular drug switch in Stage 2 with different {∆t} and fixed k * from 10: ∆t = 1 day (blue), ∆t = 4 days (red), ∆t = 7 days (green), and ∆t = 10 days (magenta). Parameters/conditions: p A = {−0.18, 0.008, 0.00075}/day, p B = {−0.9, 0.016, 0.00125}/day and {A 0 R , B 0 R } = {0.1, 0.9} (a) Time histories of total populations, C n P for n ∈ {1, 4, 7, 10} days (b) Differences between the optimal population history C * P , (i.e., when ∆t = 0) and each cases with positive ∆t. (i.e., C n P − C * P ). The inside smaller plots are same types of graphs with the bigger graphs, and show enlargement of interesting ranges.
